IDEAYA Biosciences, Inc. IDYA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| External Clinical Development Expenses by Product | ||||||
| Darovasertib | $98.56M+25.8% | $98.24M+48.4% | $102.21M+125% | $88.55M+129% | $78.35M+159% | |
| IDE161 | $6.76M-44.6% | $7.6M-38.9% | $11.06M+23.3% | $11.7M+40.9% | $12.19M+52.0% | |
| IDE397 | $14.44M-29.1% | $14.66M-25.0% | $18.73M+24.5% | $20.1M+54.8% | $20.37M+71.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does IDEAYA Biosciences, Inc. break its business down?
- IDEAYA Biosciences, Inc. (IDYA) reports external clinical development expenses by product across 7 parts — Darovasertib, IDE034, IDE161, IDE397 and IDE574. Each is extracted from the segment footnotes and tracked over time.
- Where does IDEAYA Biosciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in IDEAYA Biosciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
